Cytek Biosciences Stock Today
| CTKB Stock | USD 4.36 0.05 1.16% |
PerformanceWeakest
| Odds Of DistressLow
|
Cytek Biosciences is trading at 4.36 as of the 12th of February 2026, a 1.16 percent increase since the beginning of the trading day. The stock's open price was 4.31. Cytek Biosciences has about a 21 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 14th of November 2025 and ending today, the 12th of February 2026. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 23rd of July 2021 | Category Healthcare | Classification Health Care |
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California. The company has 127.86 M outstanding shares of which 6.54 M shares are currently shorted by private and institutional investors with about 8.03 trading days to cover. More on Cytek Biosciences
Moving against Cytek Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Cytek Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Wenbin Jiang | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, SP Small-Cap 600, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCytek Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cytek Biosciences' financial leverage. It provides some insight into what part of Cytek Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cytek Biosciences (CTKB) is traded on NASDAQ Exchange in USA and employs 692 people. Cytek Biosciences is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 551.1 M. Cytek Biosciences conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 127.86 M outstanding shares of which 6.54 M shares are currently shorted by private and institutional investors with about 8.03 trading days to cover.
Cytek Biosciences currently holds about 349.89 M in cash with 25.38 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.6.
Check Cytek Biosciences Probability Of Bankruptcy
Ownership AllocationCytek Biosciences holds a total of 127.86 Million outstanding shares. Over half of Cytek Biosciences' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cytek Ownership Details
Cytek Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.2 M | |
| Northern Trust Corp | 2025-06-30 | 1.1 M | |
| Renaissance Technologies Corp | 2025-06-30 | 1.1 M | |
| Goldman Sachs Group Inc | 2025-06-30 | 1 M | |
| Millennium Management Llc | 2025-06-30 | 924.8 K | |
| Charles Schwab Investment Management Inc | 2025-06-30 | 909.6 K | |
| Jacobs Levy Equity Management, Inc. | 2025-06-30 | 888.3 K | |
| Bank Of New York Mellon Corp | 2025-06-30 | 699.9 K | |
| Ubs Group Ag | 2025-06-30 | 632.1 K | |
| Blackrock Inc | 2025-06-30 | 17 M | |
| Vanguard Group Inc | 2025-06-30 | 7.8 M |
Cytek Biosciences Historical Income Statement
Cytek Stock Against Markets
Cytek Biosciences Corporate Management
| Todd Garland | Chief Officer | Profile | |
| Ming Yan | CTO Director | Profile | |
| Melik Ulusu | Senior Chain | Profile | |
| Mark Edinger | VP Affairs | Profile | |
| Allen Poirson | Senior Development | Profile | |
| Connie Wedel | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. Projected growth potential of Cytek fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cytek Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.735 | Earnings Share (0.11) | Revenue Per Share | Quarterly Revenue Growth 0.015 | Return On Assets |
Investors evaluate Cytek Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cytek Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Cytek Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Cytek Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytek Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cytek Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.